Simple prognostic score for metastatic castration‐resistant prostate cancer with incorporation of neutrophil‐to‐lymphocyte ratio

The neutrophil‐to‐lymphocyte ratio (NLR), a marker of inflammation, has been reported to be a poor prognostic indicator in prostate cancer. Here we explore the use of the NLR to establish a simple prognostic score for men with metastatic castration‐resistant prostate cancer (mCRPC) treated with docetaxel. METHODS: In the training cohort, the NLR and other known prognostic variables were evaluated among a cohort of chemotherapy‐naïve patients treated with thrice‐weekly docetaxel at the Princess Margaret Cancer Centre. Significant prognostic variables identified by univariable Cox regression were evaluated by the area under the receiver operating characteristic curves. Multivariable Cox regression was then used to derive a prognostic score where 1 risk point was assigned for each significant variable. The model was externally validated in a cohort of patients treated at the Royal Marsden. RESULTS: Three hudred fifty‐seven patients were analyzed in the training cohort. Median age was 71 years, 12% had liver metastasis, and median overall survival (OS) was 14.7 months. Liver metastases, hemoglobin <12 g/dL, alkaline phosphatase >2.0× upper limit of normal (ULN), lactate dehydrogenase >1.2× ULN, and NLR >3 were associated with significantly worse OS in multivariable analysis. Four risk categories were subsequently established with 0, 1, 2, and 3‐5 points. Two‐year OS rates for these categories were 43%, 37%, 12%, and 3%, respectively. Area under the curve for the training cohort was 0.78 (95% CI, 0.72‐0.84) compared with 0.66 (95% CI, 0.58‐0.74) for the 215 patients in the validation cohort. CONCLUSIONS: This simple risk score provides good prognostic and discriminatory accuracy for men with mCRPC. Cancer 2014;120:3346–3352. © 2014 American Cancer Society.

[1]  Gregory R Pond,et al.  Prognostic impact of the neutrophil-to-lymphocyte ratio in men with metastatic castration-resistant prostate cancer. , 2014, Clinical genitourinary cancer.

[2]  Ben Tran,et al.  Prognostic role of neutrophil-to-lymphocyte ratio in solid tumors: a systematic review and meta-analysis. , 2014, Journal of the National Cancer Institute.

[3]  I. Thompson,et al.  Serum biomarkers of bone metabolism in castration-resistant prostate cancer patients with skeletal metastases: results from SWOG 0421. , 2014, Journal of the National Cancer Institute.

[4]  M. Morris,et al.  Updated prognostic model for predicting overall survival in first-line chemotherapy for patients with metastatic castration-resistant prostate cancer. , 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[5]  I. Tannock,et al.  Clinical variables associated with PSA response to abiraterone acetate in patients with metastatic castration-resistant prostate cancer. , 2014, Annals of oncology : official journal of the European Society for Medical Oncology.

[6]  S. Clarke,et al.  The systemic inflammation-based neutrophil-lymphocyte ratio: experience in patients with cancer. , 2013, Critical reviews in oncology/hematology.

[7]  H. Scher,et al.  Serum androgens as prognostic biomarkers in castration-resistant prostate cancer: results from an analysis of a randomized phase III trial. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[8]  D. McMillan The systemic inflammation-based Glasgow Prognostic Score: a decade of experience in patients with cancer. , 2013, Cancer treatment reviews.

[9]  I Syndikus,et al.  Alpha emitter radium-223 and survival in metastatic prostate cancer. , 2013, The New England journal of medicine.

[10]  T. Costantino,et al.  Neutrophil to lymphocyte ratio and cardiovascular diseases: a€review , 2012 .

[11]  M. Carducci,et al.  Pretreatment neutrophil-to-lymphocyte ratio in metastatic castration-resistant prostate cancer patients treated with ketoconazole: association with outcome and predictive nomogram. , 2012, The oncologist.

[12]  C. Guillemette,et al.  Molecular Markers in Key Steroidogenic Pathways, Circulating Steroid Levels, and Prostate Cancer Progression , 2012, Clinical Cancer Research.

[13]  Kurt Miller,et al.  Increased survival with enzalutamide in prostate cancer after chemotherapy. , 2012, The New England journal of medicine.

[14]  D. McMillan,et al.  Systemic inflammation and survival of patients with prostate cancer: evidence from the Glasgow Inflammation Outcome Study , 2011, Prostate Cancer and Prostatic Diseases.

[15]  G. Pond,et al.  Prognostic stratification of post-docetaxel metastatic castration resistant prostate cancer (mCRPC) from a phase III randomized trial. , 2012 .

[16]  Ruedi Aebersold,et al.  Novel prognostic markers in the serum of patients with castration-resistant prostate cancer derived from quantitative analysis of the pten conditional knockout mouse proteome. , 2011, European urology.

[17]  D. Hanahan,et al.  Hallmarks of Cancer: The Next Generation , 2011, Cell.

[18]  M. Kattan,et al.  Predictive and prognostic models in radical prostatectomy candidates: a critical analysis of the literature. , 2010, European urology.

[19]  J. Machiels,et al.  Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial , 2010, The Lancet.

[20]  I. Tannock,et al.  The development of risk groups in men with metastatic castration-resistant prostate cancer based on risk factors for PSA decline and survival. , 2010, European journal of cancer.

[21]  K. Pienta,et al.  Circulating Tumor Cells Predict Survival Benefit from Treatment in Metastatic Castration-Resistant Prostate Cancer , 2008, Clinical Cancer Research.

[22]  I. Tannock,et al.  A Contemporary Prognostic Nomogram for Men with Hormone-Refractory Metastatic Prostate Cancer: A TAX327 Study Analysis , 2007, Clinical Cancer Research.

[23]  A. Harris,et al.  REporting recommendations for tumour MARKer prognostic studies (REMARK) , 2005, British Journal of Cancer.

[24]  P. Kantoff,et al.  Prognostic model for predicting survival in men with hormone-refractory metastatic prostate cancer. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[25]  Kevin Regan,et al.  Nomogram for overall survival of patients with progressive metastatic prostate cancer after castration. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.